Regulatory issues
The lack of dedicated guidance for digital marketing channels is regularly said to prevent pharmaceutical companies from using them, or using them more widely.
This is not without good reason. Digital marketing initiatives tend to be more visible to a larger audience than the channels pharma has traditionally focused on, so caution is understandable.
Recent articles
-
Screening digital media for potential AEs
Changes to European pharmacovigilance rules could recommend pharma companies regularly screen digital media for potential adverse events
-
European pharmacovigilance
The 2012 changes to Europe's pharmacovigilance rules could have a significant impact on digital marketing projects run by European pharmaceutical firms
-
Overcoming pharma's lack of digital regulations
The industry does have regulations that cover digital marketing, but much rests on interpretation
-
Tackling pharma’s regulatory issues in digital marketing
Limited guidance means finding out, and following, internal best practice
-
Social media’s adverse event myth
A 2011 study found that less than half a per cent of social media mentions of pharma brands contained an adverse event
Digital Intelligence Blog
- UK pharmacists get social media guidance
- Royal Pharmaceutical Society collects crowd-sourced tools and information on how to use Twitter, Facebook etc
21st May 2013 - NHS to receive £260m for patient safety technology
- Majority of hospital fund will be used for electronic prescribing
20th May 2013 - UCB and IBM to harness big data for personalised epilepsy care
- Joint project could pave the way for therapy area use of IBM's Watson
17th May 2013 - Sanofi partners with PatientsLikeMe to promote its clinical trials
- Online patient community will match patients to the pharma company's trials
16th May 2013 - Brazil eHealth pilot improves healthcare access for city poor
- Rio de Janeiro project also finds eHealth integration provides major cost savings for health system
15th May 2013
more
